19:55 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Dec. 18 with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors...
13:02 , Dec 18, 2018 |  BC Extra  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Tuesday with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors City...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
16:37 , Sep 21, 2018 |  BC Week In Review  |  Company News

Allergan to acquire botulinum neurotoxin play Bonti

Allergan plc (NYSE:AGN) will acquire Bonti Inc. (Newport Beach, Calif.) for $195 million up front. Bonti shareholders are also eligible for undisclosed commercial milestone payments. Allergan and Bonti declined to disclose details. In May, Allergan...
06:10 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

Bonti Inc. (Newport Beach, Calif.) said EB-001A improved scar appearance by about 50% vs. placebo as measured by investigator-assessed visual analog scale (VAS) scores at day 30 in the Phase IIa SHINE-1 trial in 12...
20:27 , Feb 2, 2018 |  BC Week In Review  |  Financial News

Bonti raises $15.5M in series C

Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $15.5 million on Jan. 23 in a series C round led by existing investor City Hill Ventures. Other undisclosed new and existing investors participated. The company's...
00:44 , Jan 24, 2018 |  BC Extra  |  Company News

Management tracks: Gritstone, Disarm, Symic

Cancer immunotherapy company Gritstone Oncology Inc. (Emeryville, Calif.) hired Jean-Marc Bellemin as CFO and EVP of finance. He was CFO and SVP of the Actelion Pharmaceuticals U.S. division of Actelion Ltd., which Johnson & Johnson...
21:49 , Apr 20, 2017 |  BC Week In Review  |  Financial News

Bonti completes venture financing

Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $11.7 million in a series B round on April 18. RBV Capital, City Hill Ventures, Colt Ventures, JMCR Partners and HighLight Capital participated. Existing investors also...